Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC2993 (Exenatide) Dose-Response in Type 2 Diabetes
NCT00044694Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2002
- Primary completion
- May 2003
- Countries
- 1
- Sponsor
- AstraZeneca
- Modality
- Peptides
- Drugs
- exenatide
- Conditions
- type 2 diabetes mellitus (T2DM)
01
Overview
Phase 2, randomised, triple-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (8 arms), sponsored by AstraZeneca. Primary endpoint: Change in HbA1c (glycosylated hemoglobin) at Day 28. Started Aug 2002; status: completed.
02
Design
8 arms- Study design
- RandomizedTriple-blind
Placebo 0.01 mL
Placebo 0.01 mL subcutaneously injected twice daily
Placebo 0.02 mL
Placebo 0.02 mL subcutaneously injected twice daily
Placebo 0.03 mL
Placebo 0.03 mL subcutaneously injected twice daily
Placebo 0.04 mL
Placebo 0.04 mL subcutaneously injected twice daily
AC2993 2.5 mcg
AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
AC2993 5.0 mcg
AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
2 more in the full profile.
03
Endpoints
Primary
Change in HbA1c (glycosylated hemoglobin)
Secondary
Change in HbA1c
Change in fasting plasma glucose
Change in serum fructosamine
Beyond the preview
Go deeper on NCT00044694.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044694.